PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure
PROVE-SAS-AHF
PROVE-SAS-AHF
Sponsor study identifier
interventional
54
1 country
4
Study Start
December 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 29, 2019
Actual (reported)Study Completion
May 29, 2019
Actual (reported)The prevalence of sleep-disordered breathing is common in patients with stable chronic heart failure (up to 83%). Basically, the SAS is divided into two categories: central SAS (CSAS) and obstructive SAS (OSAS). The two can coexist. In patients with CHF, the presence of SAS is associated with higher mortality. CHF is associated with a high rate of re-hospitalization and significant morbidity and mortality and is considered as a major medical and economic problem. To date, few studies have investigated the prevalence, severity, persistence and the role of SAS during cardiac decompensation. For different pathophysiological considerations, it is assumed that SAS is exacerbated during AHF. Therefore SAS is not conventionally screened during this phase. This assumption has been questioned recently by some studies which showed stability of the type of SAS and its severity between the decompensation episode and the stable HF. Our hypothesis is that SAS during an AHF episode of CHF will remain stable both in terms of severity and type at three months of decompensation. Thus early polygraphy may be reliable for identifying HF patients with SAS.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 29, 2019
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 10, 2014
Actual (reported)December 2014
Date type not reportedThis date has not been verified as actual or estimated.
December 17, 2014
Actual (reported)May 29, 2019
Actual (reported)May 29, 2019
Actual (reported)Persistence of the severity of SAS at the follow visit (AHI> 15).
2 months after AHF
type of SAS
2 months after AHF
Echocardiography parameters ECG Holter, biology
2 months after AHF
Prognostic at 1 year (mortality and rehospitalization for HF)
2 months after AHF
polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Hôpital Henri Mondor
Créteil, 94010, France
Chu Pitie Salpetriere
Paris, 75013, France
Hôpital BICHAT
Paris, 75018, France
Chu Saint Etienne
Saint-Etienne, 42100, France
54 participants (actual enrollment reported by the registry).
First Submitted
November 10, 2014
First Posted
December 17, 2014
Study Start
December 2014
Date type not reportedThis date has not been verified as actual or estimated.
Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Contact the study team to confirm eligibility.
Primary Completion
May 29, 2019
Actual (reported)Study Completion
May 29, 2019
Actual (reported)Last Updated
August 5, 2019
Record last verified: 2019-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: